For research use only. Not for therapeutic Use.
GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK)[1].
| Catalog Number | I019202 |
| CAS Number | 1620573-48-9 |
| Synonyms | 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine |
| Molecular Formula | C21H24F3N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C21H24F3N5O/c22-21(23,24)16-3-12(5-26-20(16)25)17-4-18(29(27-17)6-11-1-2-11)19-14-7-28(8-15(14)19)13-9-30-10-13/h3-5,11,13-15,19H,1-2,6-10H2,(H2,25,26)/t14-,15+,19? |
| InChIKey | IRPVABHDSJVBNZ-RTHVDDQRSA-N |
| SMILES | C1CC1CN2C(=CC(=N2)C3=CC(=C(N=C3)N)C(F)(F)F)C4C5C4CN(C5)C6COC6 |
| Reference | [1]. Le Pichon CE, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017 Aug 16;9(403). pii: eaag0394. |
